BiotechTube
Home/Talisman Therapeutics/James Smith
JS

James Smith

Head of Scientific Operations

Talisman Therapeutics

Therapeutic Areas

Alzheimer's DiseaseNeurodegenerative Diseases

Talisman Therapeutics Pipeline

DrugIndicationPhase
Lysosome Biology ProgramNeurodegenerative DiseasesPreclinical
Pathogenic Protein Reduction ProgramNeurodegenerative Diseases (e.g., Alzheimer's)Preclinical
Microglial Health ProgramNeurodegenerative DiseasesPreclinical

Leadership Team at Talisman Therapeutics

RL
Rick Livesey
Chief Executive Officer
ES
Emily Scraggs
Commercial Director
JM
J. Mark Treherne
Chairman of the Board
View full Talisman Therapeutics profile